Jenburkt Pharmaceuticals Ltd — Others, 20-05-2025: Corp Action

Jenburkt Pharmaceuticals has announced a board meeting to approve the financial results for the quarter and financial year ended March 31, 2025. The company reported revenue from operations of ₹151.69 Cr and profit after tax of ₹32.06 Cr for the year, showing growth over the previous year. The board approved a 180% dividend on equity shares and slated the 40th Annual General Meeting to be held via video conferencing. Shri Ashish Uttam Bhuta is re-appointed as Chairman and Managing Director for five years starting April 1, 2026, with remuneration terms approved for three years. The auditors issued an unmodified opinion and confirmed effective internal financial controls.